- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05557487
Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration (TRIO)
Taiwan Real-world Low-dose Computed Tomography Screening behavIor and Outcome Research for High Risk Subjects Based on Health Promotion Administration-part A: Questionnaire Survey -Part B: LDCT Screening Outcome and Management
Lung cancer is the leading cause of mortality in the world, and also in Taiwan.Despite the researches and availability in new therapies, it causes the highest mortality and is one of the most preventable cancers as well. Smoking is the most common cause of lung cancer worldwide. Compared to lung cancer in smokers, lung cancer in never-smokers is associated with East Asian ethnicity, female sex, and adenocarcinoma histology. This unique risk group is likely to have distinct molecular drivers, especially EGFR, ALK, and ROS1 mutations.In National Taiwan Cancer Registry data, more than half (53%) of all newly diagnosed lung cancer patients and 93% of female patients are lifelong never-smokers. This scenario is common in East Asia. It is essential to develop a different strategy for screening lung cancer patients with other high-risk profiles. Several risk factors have been identified in never-smoking lung cancer and one of the most important factor is a lung cancer family history (LCFH) in a first-degree relative. Other high-risk occupational or environmental factors include air-pollution exposed occupations (such as traffic policeman and street cleaners) for at least 10 years, cooking index ≥ 110, defined as 2/7 * days cooking by pan frying, stir frying, or deep frying in one week * years cooking, cooking without using ventilation, passive smoke exposure, and history of pulmonary tuberculosis or chronic obstructive pulmonary disorders.
As described above, three high risk groups are interested in this study, the previous heavy smokers (group 1); those who has family history (group 2) and those who have high risk occupation or environment factors (group 3). From the published researches, we assume the detection rate to be 1.1% for group 1 based on NLST results16, 2.6% for group 2 (395 out of 12,011 subjects in TALENT), and we assume the detection Group 3 to be 1% after consulting board-certified senior specialists in this field.
This is a prospective, multi-center, single arm study in Taiwan of subjects who are eligible to receive LDCT screening based on recommendation of Health Promotion Administration of Taiwan.
The primary objective of TRIO part A is the LDCT screening acceptance rate of high lung cancer risk subjects.
The primary objective of TRIO part B is the exact lung cancer detection rates in these three groups.
Other secondary objectives are also included.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: GEECHEN CHANG, MD. PhD
- Phone Number: 34414 +886-4-24739595
- Email: geechen@gmail.com
Study Locations
-
-
-
Hsinchu, Taiwan
- Recruiting
- National Taiwan University Hospital Hsin-Chu Branch
-
Contact:
- Chong-Jen Yu, MD PhD
-
Hualien City, Taiwan, 970473
- Recruiting
- Hualien Tzu Chi Hospital
-
Contact:
- Chung-Ping Hsu, MD PhD
-
Kaohsiung, Taiwan
- Recruiting
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Contact:
- Inn-Wen Chong, MD PhD
-
Kaohsiung, Taiwan
- Not yet recruiting
- E-DA Hospital
-
Contact:
- Yu-Feng Wei, MD PhD
-
New Taipei City, Taiwan
- Not yet recruiting
- Ministry of Health and Welfare Shuang-Ho Hospital
-
Contact:
- Po-Hao Feng, MD PhD
-
Taichung, Taiwan, 402
- Recruiting
- Chung Shan Medical University
-
Contact:
- GEECHEN CHANG, MD, PhD
- Phone Number: 34414 +886-4-24739595
- Email: geechen@gmail.com
-
Taipei city, Taiwan
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Chao-Chi Ho, MD PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Group 1: Previous heavy smokers Age 50 to 80 years, meet both criteria in the followings.
- Cigarette smoking of at least 20 pack-years
- With successful smoking cessation history (stopping smoking for more than 6 months), but less than 15 years
Group 2: First-degree relatives of lung cancer patients
- aged more than 50 years
- age less than 50 years old, but older than the age at diagnosis of the youngest lung cancer proband in the family
Group 3: With other high-risk occupational or environmental factors Age 50 to 80 years, meet one or more of the following criteria.
- air-pollution exposed occupations (such as traffic policemen, and street cleaners….) for at least 10 years
- cooking index ≥ 110, defined as 2/7 * days cooking by pan frying, stir-frying, or deep frying in one week * years cooking.
- cooking without using ventilation for more than 20 years
- history of pulmonary tuberculosis and complete anti-tuberculosis treatment with intervals more than 5 years before this study
Exclusion Criteria:
- previous history of lung cancer
- another malignancy except for cervical carcinoma in situ or non-melanomatous carcinoma of the skin within 5 years
- an inability to tolerate transthoracic procedures or thoracotomy
- chest CT examination was performed within 18 months
- hemoptysis of unknown etiology within one month
- body weight loss of more than 6 kg within one year without an evident cause
- a known pregnancy
- Not capable of understanding or responding to the written questionnaire even through the help from the study team
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Previous heavy smokers
Age 50 to 80 years who have at least a 20-pack-year smoking history with successful smoking cessation history (stopping smoking for more than 6 months), but less than 15 years
|
|
First degree relatives of lung cancer patients
First-degree relatives of lung cancer patients
|
|
With other high-risk occupational or environmental factors
Age 50 to 80 years, meet one or more of the following criteria.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of willingness and completeness of LDCT screening after the detailed questionnaire survey for the eligible participants.
Time Frame: 2 years
|
|
2 years
|
To investigate overall lung cancer detection rate of high lung cancer risk individuals
Time Frame: 2 years
|
Cytological or Pathological proof of lung cancer to investigate the overall lung cancer detection rate
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
- Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, Chiles C, Black WC, Aberle DR; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014 Feb 1;174(2):269-74. doi: 10.1001/jamainternmed.2013.12738. Erratum In: JAMA Intern Med. 2014 May;174(5):828.
- Kim H, Kim HY, Goo JM, Kim Y. Lung Cancer CT Screening and Lung-RADS in a Tuberculosis-endemic Country: The Korean Lung Cancer Screening Project (K-LUCAS). Radiology. 2020 Jul;296(1):181-188. doi: 10.1148/radiol.2020192283. Epub 2020 Apr 14.
- de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
- National Lung Screening Trial Research Team; Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013 May 23;368(21):1980-91. doi: 10.1056/NEJMoa1209120.
- US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Landefeld CS, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Mar 9;325(10):962-970. doi: 10.1001/jama.2021.1117.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS1-22111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); New York University; Stanford UniversityRecruitingSmoking | Smoking, Tobacco | Smoking, CigaretteUnited States
Clinical Trials on Low dose computed tomography
-
Xuzhou Central HospitalCompletedLung Cancer | Lung; NodeChina
-
Xuzhou Central HospitalCompletedLung Cancer, Adenocarcinoma | Lung Inflammatory PseudotumorChina
-
University of CalgaryAlberta Cancer Foundation; Western Canadian Mesothelioma FoundationTerminatedLung Cancer | MesotheliomaCanada
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States
-
Massachusetts General HospitalAgency for Healthcare Research and Quality (AHRQ)Recruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Shanghai Chest HospitalUnknown
-
Cancer Prevention and Research Institute, ItalyUniversity of Pisa; Careggi Hospital; University of Florence; Local Health Authority...Completed
-
Azienda Ospedaliero-Universitaria di ParmaCompletedChronic Obstructive Pulmonary Disease
-
Shanghai Chest HospitalUnknown